Depression in Parkinson's disease: Diagnosis and treatment;Depressão na doença de Parkinson: Diagnóstico e tratamento

Arquivos de Neuro-Psiquiatria

Volumn 70, Issue 8, 2012, Pages 617-620

  Costa, Flavio Henrique de Rezende ^a   Rosso, Ana Lucia Zuma ^a   Maultasch, Henryk ^a   Nicaretta, Denise Hack ^b   Vincent, Maurice Borges ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Depression; Non motor symptoms; Parkinson disease

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DULOXETINE; ESCITALOPRAM; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANHEDONIA; DEPRESSION; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; PARKINSON DISEASE; PRESCRIPTION; PREVALENCE; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 84865366981     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2012000800011     Document Type: Review

References (34)

1. Chaudhuri KR, Naidu Y. Early Parkinson's disease and non-motor issues. J Neurol 2008;255 (Suppl 5):S33-S38.
2. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
3. Merello M. Non-motor disorders in Parkinson's disease. Rev Neurol 2008;47:261-270.
4. Müller T. Drug treatment of non-motor symptoms in Parkinson's disease. Expert Opin Pharmacother 2002;3:381-388.
5. Lemke MR. Dopamine agonists in the treatment of non-motor symptoms of Parkinson's disease: depression. Eur J Neurol 2008;15 (Suppl 2):S9-S14.
6. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223-236.
7. Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic arkinson's disease. Adv Anat Embryol Cell Biol. 2009;201:1-119.
8. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, SandmannKeil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249 (Suppl 3):S1-S5.
9. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Dis 2009;24:1641-1649.
10. Antonini A, Colosimo C, Marconi R, Morgante L, Barone P. The PRIAMO study: background, methods and recruitment. Neurol Sci 2008;29:61-65.
11. Antonini A. Unraveling depression in Parkinson's disease. Eur J Neurol 2008;15:885-886.
12. Schrag A. Quality of life and depression in Parkinson's disease. J. Neurol Sci 2006;248:151-157.
13. Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Dis 2000;15:1112-1118.
14. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
15. Prado RC, Barbosa ER. Depression in Parkinson's disease: study of 60 cases. Arq Neuropsiquiatr 2005;63:766-771.
16. Weintraub D, Stern MB. Psychiatric complications in Parkinson disease. Am J Geriatr Psychiatry 2005;13:844-851.
17. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009;24:2175-2186.
18. Leentjens AFG. The Validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 2000;15:1221-1224.
19. García-Ramos R, Villanueva C, Del Val J, Matías-Guíu J. Apathy in Parkinson's disease. Neurologia 2010;25:40-50.
20. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74:924-931.
21. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
22. Aarsland D, Emre M, Lees A, Poewe W, Ballard C. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007;68:80; author reply 81.
23. Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2008;23:631-640.
24. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.
25. Marino S, Sessa E, Di Lorenzo G, et al. Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. Neurol Sci 2008;29:391-395.
26. Weintraub D, Comella CL, Horn S. Parkinson's disease--Part 3: neuropsychiatric symptoms. Am J Manag Care 2008;14:S59-S69.
27. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75:448-455.
28. Montgomery EB. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007;68:81; author reply 81.
29. Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. Med Hypotheses 2010;75:544-546.
30. Picillo M, Rocco M, Barone P. Dopamine receptor agonists and depression in Parkinson's disease. Parkinsonism Relat Disord 2009;15 (Suppl 4):S81-S84.
31. Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008;22:563-586.
32. Dias-Tosta E, CRd MR Borges V, Correa Neto Y Doença de Parkinsonrecomendações. Academia Brasileira de Neurologia 2011;1:62-64.
33. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26 (Suppl 3):S42-S80.
34. Fregni F, Pascual-Leone A. Transcranial magnetic stimulation for the treatment of depression in neurologic disorders. Curr Psychiatry Rep 2005;7:381-390.